2023 ACR/EULAR antiphospholipid syndrome classification criteria

被引：139

作者：

Barbhaiya, Medha ^{[1
]}

Zuily, Stephane ^{[2
,3
]}

Naden, Ray ^{[4
]}

Hendry, Alison ^{[5
]}

Manneville, Florian ^{[6
]}

Amigo, Mary-Carmen ^{[7
]}

Amoura, Zahir ^{[8
]}

Andrade, Danieli ^{[9
]}

Andreoli, Laura ^{[10
]}

Artim-Esen, Bahar ^{[11
]}

Atsumi, Tatsuya ^{[12
]}

Avcin, Tadej ^{[13
]}

Belmont, Michael H. ^{[14
]}

Bertolaccini, Maria Laura ^{[15
]}

Branch, D. Ware ^{[16
]}

Carvalheiras, Graziela ^{[17
]}

Casini, Alessandro ^{[18
]}

Cervera, Ricard ^{[19
]}

Cohen, Hannah ^{[20
]}

Costedoat-Chalumeau, Nathalie ^{[21
]}

Crowther, Mark ^{[22
]}

de Jesus, Guilherme ^{[23
]}

Delluc, Aurelien ^{[24
,25
]}

Desai, Sheetal ^{[26
]}

De Sancho, Maria ^{[27
]}

Devreese, Katrien M. ^{[28
,29
]}

Diz-Kucukkaya, Reyhan ^{[30
]}

Duarte-Garcia, Ali ^{[31
]}

Frances, Camille ^{[32
]}

Garcia, David ^{[33
]}

Gris, Jean-Christophe ^{[34
]}

Jordan, Natasha ^{[35
]}

Leaf, Rebecca K. ^{[36
]}

Kello, Nina ^{[37
]}

Knight, Jason S. ^{[38
]}

Laskin, Carl ^{[39
]}

Lee, Alfred I. ^{[40
]}

Legault, Kimberly ^{[41
]}

Levine, Steve R. ^{[42
,43
]}

Levy, Roger A. ^{[44
,45
]}

Limper, Maarten ^{[46
]}

Lockshin, Michael D. ^{[1
]}

Mayer-Pickel, Karoline ^{[47
]}

Musial, Jack ^{[48
]}

Meroni, Pier Luigi ^{[49
]}

Orsolini, Giovanni ^{[50
]}

Ortel, Thomas L. ^{[51
]}

Pengo, Vittorio ^{[52
]}

Petri, Michelle ^{[53
]}

Pons-Estel, Guillermo ^{[54
]}

机构：

[1] Weill Cornell Med, Hosp Special Surg, Barbara Volcker Ctr Women & Rheumat Dis, New York, NY USA

[2] Univ Lorraine, French Natl Referral Ctr System & Autoimmune Dis, Vasc Med Div, Inserm,DCAC, Nancy, France

[3] CHRU Nancy, Nancy, France

[4] Auckland City Hosp, Dept Med & Obstet, Auckland, New Zealand

[5] Middlemore Hosp, Dept Gen Med, Auckland, New Zealand

[6] Univ Lorraine, Inserm, CHRU Nancy, CIC Clin Epidemiol, Nancy, France

[7] ABC Med Ctr, Dept Internal Med, Serv Rheumatol, Mexico City, Mexico

[8] Sorbonne Univ, Ctr Immunol & Malad Infect,Hop Pitie Salpetriere, French Natl Reference Ctr System Lupus Erythemat, Antiphospholipid Antibody Syndrome,Serv Med Inter, Paris, France

[9] Univ Sao Paulo, Dept Rheumatol, Sao Paulo, Brazil

[10] Univ Brescia, Rheumatol & Clin Immunol Unit, ASST Spedali Civili, Dept Clin & Expt Sci, Brescia, Italy

[11] Istanbul Univ, Sch Med, Dept Rheumatol, Istanbul, Turkiye

[12] Hokkaido Univ, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan

[13] Univ Ljubljana, Univ Med Ctr, Childrens Hosp, Dept Allergol Rheumatol & Clin Immunol, Ljubljana, Slovenia

[14] NYU, Hosp Joint Dis, Dept Rheumatol, New York, NY USA

[15] Kings Coll London, Sch Cardiovasc & Metab Med & Sci, Acad Dept Vasc Surg, London, England

[16] Univ Utah Hlth, Dept Obstet & Gynecol, Salt Lake City, UT USA

[17] Ctr Hosp Porto, Hosp Santo Antonio, Unidade Imunol Clin, Porto, Portugal

[18] Univ Hosp Geneva, Div Angiol & Hemostasis, Geneva, Switzerland

[19] Univ Barcelona, Hosp Clin, Dept Autoimmune Dis, Barcelona, Spain

[20] UCL, Dept Haematol, London, England

[21] Univ Paris, Hop Cochin, AP HP, Serv Med Interne,Ctr Reference Malad Autoimmune &, Paris, France

[22] McMaster Univ, Dept Med, Hamilton, ON, Canada

[23] Univ Estado Rio de Janeiro, Dept Obstet, Rio De Janeiro, Brazil

[24] Univ Ottawa, Dept Med, Ottawa, ON, Canada

[25] Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[26] Univ Calif Irvine, Div Rheumatol, Irvine, CA USA

[27] Weill Cornell Med, Div Hematol & Oncol, New York, NY USA

[28] Ghent Univ Hosp, Dept Lab Med, Coagulat Lab, Ghent, Belgium

[29] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium

[30] Istanbul Univ, Dept Mol Biol & Genet, Sch Sci, Istanbul, Turkiye

[31] Mayo Clin, Div Rheumatol, Rochester, MN USA

[32] Tenon Hosp, Dept Dermatol Allergol, Paris, France

[33] Univ Washington, Dept Hematol, Seattle, WA USA

[34] Univ Montpellier, UMR UA11, INSERM, Dept Hematol,CHRU Nimes, Montpellier, France

[35] Addenbrookes Hosp, Dept Rheumatol, Cambridge, England

[36] Massachusetts Gen Hosp, Dept Hematol, Boston, MA USA

[37] Northwell Hlth, Div Rheumatol, New York, NY USA

[38] Univ Michigan, Div Rheumatol, Ann Arbor, MI USA

[39] Univ Toronto, TRIO Fertil, Div Rheumatol, Toronto, ON, Canada

[40] Yale Sch Med, Dept Hematol, New Haven, CT USA

[41] McMaster Univ, Div Rheumatol, Hamilton, ON, Canada

[42] Suny Downstate Hlth Sci Univ, Downstate Stroke Ctr, Kings Cty Hosp Ctr, Brooklyn, NY USA

[43] Jaffe Stroke Ctr, Maimonides Med Ctr, Brooklyn, NY USA

[44] Univ Estado Rio de Janeiro, Dept Rheumatol, Rio De Janeiro, Brazil

[45] GlaxoSmithKline, Collegeville, PA USA

[46] Univ Utrecht, Univ Med Ctr, Dept Med & Clin Immunol, Utrecht, Netherlands

[47] Med Univ Graz, Dept Obstet, Graz, Austria

[48] Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland

[49] IRCCS Ist Auxol Italiano, Immunorheumatol Res Lab, Milan, Italy

[50] Univ Hosp Verona, Dept Rheumatol, Verona, Italy

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 10期

关键词：

antiphospholipid syndrome; thrombosis; antibodies; antiphospholipid; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-SCLEROSIS; ISCHEMIC-STROKE; ANTIBODIES; DIAGNOSIS; UPDATE;

D O I：

10.1136/ard-2023-224609

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators' consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-beta(2)-glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.

引用

页码：1258 / 1270

页数：13

共 50 条

[31] RELATIONSHIP BETWEEN THE PRESENCE AND LEVELS OF ANTIPHOSPHOLIPID SYNDROME ANTIBODIES AND THE CLINICAL AND DEMOGRAPHIC MANIFESTATIONS INCLUDED IN THE SYDNEY (2004) AND ACR/EULAR 2023 CLASSIFICATION CRITERIA
Morales, A. C. Veloza
Puiggros-Ferrer, A.
Bou, N.
Galarza, D.
Perello, H. Sirera
Farrerons, C. Ayza
Pitarch, O. Escarpenter
Pros, A.
Salman-Monte, T.
Perez-Garcia, C.
Monfort, J.
Carrion-Barbera, I.
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
[32] Performance of the 2023 American College of Rheumatology/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Cime-Ake, Erik
Hernandez-Molina, Gabriela
Llorente-Chavez, Amaya
Martin-Nares, Eduardo
ARTHRITIS & RHEUMATOLOGY, 2024, 76 (12) : 1775 - 1779
[33] EULAR/ACR classification criteria for SLE
Aringer, Martin
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 : S14 - S17
[34] 2023 ACR/EULAR classification criteria in existing research cohorts: an international study
Foddai, Silvia G.
Radin, Massimo
Cecchi, Irene
Rubini, Elena
Barinotti, Alice
Alba, Paula
Alonso, Carla Gimen
Rossi, Daniela
Roccatello, Dario
Sciascia, Savino
RHEUMATOLOGY, 2024, 63 (10) : 2770 - 2775
[35] THE EULAR/ACR CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC SCLEROSIS
van den Hoogen, F. H. J.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S71 - S71
[36] Diagnosis of antiphospholipid syndrome based on 2023 ACR/EULAR versus 2006 Sydney criteria, in a population of patients from Cadiz, Spain
Galan Picon, Javier
Gutierrez Serrudo, Joel
Pedrosa Garcia, Lucia
Serrano Garcia, Isabel
Rodriguez, Carmen
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 991 - 991
[37] New EULAR/ACR Classification Criteria for SLE
Specker, C.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (10): : 860 - 860
[38] Comparative Performance of ELISA and CLIA Against the 2023 ACR/EULAR APS Classification Criteria
Zigon, Polona
Bostic, Nika
Rotar, Ziga
Ambrozic, Ales
Blokar, Elizabeta
Ogric, Manca
Cucnik, Sasa
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 212 - 214
[39] The Performance of 2023 American College of Rheumatology (ACR) / European Alliance of Associations for Rheumatology (EULAR) Antiphospholipid Syndrome Classification Criteria in a Real-World Rheumatology Department
Usta, Ahmet
Yayla, Mucteba Enes
Uslu, Emine
Sezer, Serdar
Us, Ebru
Ates, Askin
Turgay, Murat
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
[40] The ACR/EULAR Classification Criteria for Systemic Sclerosis (SSc)
Pope, Janet
Khanna, Dinesh
Fransen, Jaap
Johnson, Sindhu
Baron, Murray
Tyndall, Alan
Matucci-Cerinic, Marco
Naden, Raymond
van den Hoogen, Frank
JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 951 - 951

← 1 2 3 4 5 →